Vistaril
(Hydroxyzine Hydrochloride)ApprovedSmall molecule
PfizerVistaril is one of 45 small molecule programs targeting Anxiety. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
44
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
61 competitors in Anxiety
#DrugCompanyPhaseTrials
1Versed
CConrado Roberto Hoffmann Filho
Approved
Lexapro
AbbVieApproved
Ritalin
NovartisApproved
Cymbalta
Jazz PharmaceuticalsApproved
Neupro
UCBApproved
Buspar
Bristol-Myers SquibbApproved
Xanax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Namenda
AbbVieApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Anxiety2 trials
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
VISTARIL
NDA NDA011459
Jan 1, 1982
VISTARIL
NDA NDA011111
Jan 1, 1982
VISTARIL
NDA NDA011795
Jan 1, 1982
ATARAX
NDA NDA010485
Jan 1, 1982
ATARAX
NDA NDA010392
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Hydroxyzine Hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]